Chronic Lymphocytic Leukemia News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Chronic Lymphocytic Leukemia Market Comprehensive Insights 2017 - Research of Market



Chronic Lymphocytic Leukemia Market Comprehensive Insights 2017 
Research of Market
Chronic Lymphocytic Leukemia (CLL)-Mechanism of action Insights, 2017?, report provides comprehensive insights of the ongoing therapeutic research and development across Chronic Lymphocytic Leukemia (CLL). The report provides a complete ...

and more » 


Study Shows Cancer Patients Are Choosing Less Severe Side ... - Technology Networks



Technology Networks
 
Study Shows Cancer Patients Are Choosing Less Severe Side ... 
Technology Networks
When choosing their preferred treatment, people with chronic lymphocytic leukemia (CLL) place the highest value on medicines that deliver the longest ...

and more » 


#ASH17: Late breaker from AbbVie, Roche highlights a blockbuster breakout opportunity for Venclexta in CLL - Endpoints News



Endpoints News
 
#ASH17: Late breaker from AbbVie, Roche highlights a blockbuster breakout opportunity for Venclexta in CLL 
Endpoints News
When AbbVie $ABBV and Roche $RHHBY won approval for Venclexta (venetoclax) back in the spring of 2016 as a new treatment for chronic lymphocytic leukemia, the pharma giants had some big revenue numbers in mind. And with some new data that's ...

 


Chronic Lymphocytic Leukaemia: KOL Insight 2017 - PR Newswire (press release)



Chronic Lymphocytic Leukaemia: KOL Insight 2017 
PR Newswire (press release)
Learn how KOLs see the market evolving, and how they expect developers to differentiate their pipeline therapies in KOL Insight: Chronic Lymphocytic Leukaemia (CLL). Twelve US and European KOLs provide their candid insights on seven marketed ...

and more » 


ASCO Value Framework Challenging to Apply in CLL - Cancer Network



ASCO Value Framework Challenging to Apply in CLL 
Cancer Network
... of Clinical Oncology (ASCO) Value Framework is an important step to quantify the value of cancer therapies, a new study has found that it has essential limitations for its application in clinical practice for the treatment of chronic lymphocytic ...

 


FDA lifts second trial hold for Prescient's lead drug, with one to go - FierceBiotech



FierceBiotech
 
FDA lifts second trial hold for Prescient's lead drug, with one to go 
FierceBiotech
Gilead's Zydelig (idelalisib)?approved for chronic lymphocytic leukemia and two types of lymphoma?was the first drug targeting the pathway to reach the market but has been knocked back commercially by toxicity issues. In September Bayer's PI3K ...

 


Relapsed Chronic Lymphocytic Leukemia Market Analysis 2017 - Research of Market



Relapsed Chronic Lymphocytic Leukemia Market Analysis 2017 
Research of Market
Relapsed Chronic Lymphocytic Leukemia-Mechanism of action Insights, 2017?, report provides comprehensive insights of the ongoing therapeutic research and development across Relapsed Chronic Lymphocytic Leukemia. The report provides a complete ...

and more » 


How Teva's Respiratory and Oncology Portfolios Are Positioned after 3Q17 - Market Realist



How Teva's Respiratory and Oncology Portfolios Are Positioned after 3Q17 
Market Realist
Treanda is used to treat individuals with CLL (chronic lymphocytic leukemia). Treanda's competition in the CLL drug market includes Johnson & Johnson's (JNJ) Imbruvica, Gilead Sciences' (GILD) Zydelig, and Novartis (NVS) Arzerra. In 3Q17, Imbruvica and ...

and more » 


Roche, AbbVie leukemia drug superior to older medicine in study - WHTC



Roche, AbbVie leukemia drug superior to older medicine in study 
WHTC
Venclexta, sold by Roche and AbbVie, received an accelerated approval to treat chronic lymphocytic leukemia (CLL) patients with a specific genetic mutation who received at least one prior therapy. But its continued approval, which was based only on ...

and more » 


Profiling CLL Patients Likely to Progress on Available Agents - OncLive



OncLive
 
Profiling CLL Patients Likely to Progress on Available Agents 
OncLive
The 4 primary causes of treatment failure for patients with CLL are disease progression, Richter's transformation, adverse events, and secondary cancers, including myelodysplastic syndrome and acute myeloid leukemia. Furman, director of the CLL ...
Online Only LWW Journals (blog)

all 3 news articles »